简介：AIM:Tocharacterizetemporalpatternofresolutionandrecurrenceofnaivechoroidalneovascularization(CNV)secondarytowetage-relatedmaculardegeneration(AMD)treatedwithintravitrealbevacizumabonasneededregimen,andtoanalyzebaselineriskfactorsforCNVresolutionorrecurrence.METHODS:Ninety-oneeyesof80patientswithnewlydiagnosedwetAMDwereretrospectivelystudied.Alleyesweretreatedwitharoundofthreemonthlyintravitrealbevacizumabinjections,followedbyoneadditional’bonus’injectionafterresolutionofCNVactivity.Duringfollow-up,eyesweremonitoredwithfluoresceinangiography,opticalcoherencetomography,andbest-correctedvisualacuity(BCVA).IncaseofrecurrencesofCNVactivity,eyeswereretreatedwithotherroundsofbevacizumabinjectionsfollowingthesametreatmentprotocol.RESULTS:Overamedianfollow-upof532d,themedianresolutiontimeofCNVactivityinthefirst,second,andthirdtreatmentroundwas98d,126d,and111d,respectively.Themedianrecurrencetimeforthethreeroundswas154d,126d,and151d,respectively.Nosignificantdifferenceinresolutiontime(P=0.09)orinrecurrencetime(P=0.11)wasdetectedamongtreatmentrounds.Age(P=0.0082)andlensstatus(P=0.035)werefoundtobeassociatedwithCNVresolution;forevery1-yearincreaseinagetherewas4%greaterchanceofCNVresolution;Phakiceyesdemonstrateda33%betterchancetoexperienceCNVresolutionthanpseudophakiceyes.ForCNVrecurrence,lensstatus(P=0.0009)andgender(P=0.0446)werefoundtobepredictive;pseudophakiceyeshada3.69-foldgreaterrisktoexperiencerecurrenceofCNVactivitycomparedtophakiceyes;maleshada2.19-foldgreaterrisktoexperiencerecurrenceofCNVactivitythanfemales.NosignificantBCVAchangesamongthreetreatmentroundswerenoted(P=0.56).CONCLUSION:ResolutiontimeandrecurrencetimeofCNVactivitywerenotsignificantlydifferentamongtreatmentrounds,suggestingabsenceoftachyphylaxistobevacizumab.Acautiousdecisionshouldbemadeupondisco

简介：AIM:Todeterminewhethersinglenucleotidepolymorphism(SNP)rs641153isassociatedwiththeriskofage-relatedmaculardegeneration(AMD),weperformedasystematicmeta-analysisof15eligiblestudies.SNPinthecomplementfactorB(CFB)geneisconsideredtohavesignificantassociationwithAMDsusceptibility,butthereisgreatdiscrepancyintheseresults.METHODS:TheeligiblestudieswereidentifiedbysearchingthedatabasesofPubMed,EMBASE,andWebofScience.Oddsratios(ORs)with95%confidenceintervals(CIs)wereusedtoassesstheassociation.AlldatawereanalyzedusingStatasoftware.RESULTS:Theassociationbetweenrs641153andAMDriskwasstatisticallysignificantunderthehomozygousmodel(AAvsGG:OR=0.26,95%CI=0.15-0.45,P_h=0.973,/~2=0.0%,fixedeffects),dominantmodel(AA+GAvsGG:OR=0.49,95%CI=0.40-0.59,P_h=0.004,/~2=56.4%,randomeffects)andrecessivemodel(AAvsGA+GG:OR=0.30,95%CI=0.17-0.51,R_n=0.983,I~2=0.0%,fixedeffects).Thesameresultswerealsoobservedinthestratifiedanalysesbyethnicity,sourceofcontrolandsamplesize.CONCLUSION:Ourmeta-analysissuggeststhatrs641153intheCFBgenemayplayaprotectiveroleinAMDsusceptibility,thelateAMDinparticular,bothinCaucasiansandinAsians.

简介：AIM:Toevaluatetheefficacy,safetyandstabilityofposteriorchamberphakicintraocularlensimplantationforthecorrectionofhighmyopia.METHODS:Retrospectivecasereviewof82eyes(43patients)undergoingimplantableColiamerlens(ICL)placementbyasinglesurgeon(Xiao-WeiGao)tocorrectpreoperativemeansphericalequivalentsbetween-9.00diopter(D)and-23.00D.Mainoutcomemeasuresincludeduncorrectedvisualacuity(UCVA),refraction,bestspectacle-correctedvisualacuity(BSCVA),endothelialcelldensity(ECD),intraocularpressure(IOP),lenstransparency,postoperativeuveitis.Visanteanteriorsegmentopticalcoherencetomography(AS-OCT)wasusedtomeasureanteriorchamberdepth(ACD)andthepositionofICL.RESULTS:Meanfollow-upwas6.54±3.26months(range3-12months).Predictabilityofthemanifestsphericalequivalent(SE)refractiontowithin±1.OODwasachievedin88%ofeyesand±0.50Din72.5%ofeyes.ThemeanpostoperativemanifestSErefractionwas-1.85±0.72D,with96.34%ofeyesmaintainingorgaining≥1line(s)ofBSCVA.Themean3-monthpostoperativeECDdecreasedbuthadnostatisticallydifferencecomparedwiththepreoperativeECD.Ofthe7eyes(8.54%)withamildtransientincreaseinintraocularpressure(upto30mmHg),nonerequiredasecondsurgicalprocedureorprolongedtopicalmedication.Therewasnolossoflenstransparency.Pigmentedprecipitateswereobservedin5eyes(6.09%).ThemeanpreoperativeACDmeasuredwithAS-OCTwas3.28±0.14mm,threemonthsaftersurgery,themeanACDwas2.45±0.22mm.Anteriorchamberdepthshowedastatisticallysignificantreduction.Oneeye(1.22%)hadICLspontaneousrotation,81eyes(98.78%)ofthelensremainedcorrectlycentered.CONCLUSION:TheimplantationofICLisaneffectivesurgicaloptionforthemanagementofhighmyopia.Butitslongtimeeffectandsafetystillneedmoretimetoprove.

简介：AIM:ToexploretheinhibitoryeffectofasustainedcyclosporinA(CsA)deliverymicrosphere(CsA-MS)onposteriorcapsularopacification(PCO)inrabbiteyesaftercataractextraction.·METHODS:TwentyNewZealandwhiterabbitsacceptedcataractextractionplusintraocularlensimplantationandtheirlefteyeswereintraoperativelyinjectedCsA-MSpreparedusingpolymerpolylactioglycolicacid(PLGA)asacarrierandtheirrighteyeswereinjectedwithemptyMS.Thechangesincornea,anteriorchamberreaction,intraocularpressure,PCOandCsAconcentrationinaqueoushumorwereexaminedpostoperativelyandalltheeyeswereenucleated3monthsaftersurgeryforhistopathologicalandmorphologicalexaminationwithlightmicroscopyandelectronmicroscopy.·RESULTS:Conjunctivalhyperemia,cornealedema,intraocularpressureandanteriorchamberresponseofexperimentalandcontroleyesweresimilar,whilePCOinCsAMSinjectedeyeswasgreatlyimprovedcomparedwiththatincontroleyes.PosteriorcapsulesinCsA-MSinjectedeyesweresmoothandlensepithelialcells(LEC)didnotproliferatesignificantly(P>0.05),whileLECinposteriorcapsuleofcontroleyeshaddifferentdegreesofproliferationandcorticalregeneration.LECinCsA-MSinjectedeyeswerenotfunctionallyactiveandunderwentapoptosis,whereasLECincontroleyeswerefunctionallyactive(F-test,P=0.025).Inaddition,thecornealultrastructureshowednodifferencesbetweenCsA-MSandMSinjectedeyes.CONCLUSION:CsA-MShashighbioavailabilityinrabbiteyesandcouldinhibitpostoperativePCOoccurrenceanddevelopmentduringthestudyperiod,suggestingthatCsA-MSmaybeapromising,effectiveandsafeadministrationroutetopreventPCOinclinic.

简介：AIM:ToIntroduceanewspecializedvisualacuitychartforamblyopicchildrenaged3-5yearsoldanditsclinicalapplications.METHODS:ThenewvisualacuitychartandnotationsweredesignedbasedonWeber-Fechnerlaw.Theoptotypeswereredagainstawhitebackgroundandwerespeciallyshapedfourbasicgeometricsymbols:circle,square,triangle,andcross.Aregulargeometricprogressionoftheoptotypesizesanddistributionwasemployedtoarrangein14lines.Theprogressionrateoftheoptotypesizebetweentwolineswas1.2589andthetestingdistancewas3m.VisualacuityscorecouldberecordedaslogMARnotationordecimalnotation.Agestratifieddiagnosticcriteriaforamblyopiaestablishedbyconsensusstatementondiagnosisofamblyopia(2011)amongmembersoftheStrabismusandPediatricOphthalmologyGroup,OphthalmologySociety,ChineseMedicalAssociation(SPOGOSCMA)wereillustratedinthenewvisualacuitychart.RESULTS:Whenassessingvisualacuityinchildrenaged3-5yearsold,thisnewvisualacuitychartthatconsistsoffoursymmetricalshapes(triangle,square,cross,andcircle)overcameaninabilitytorecognizethelettersofthealphabetanddifficultiesindesignatingthedirectionofblackabstractsymbolssuchasthetumbling’E’orLandolt’C’,whichthesubjectswerepronetoloseinterestin.Thevisualacuityscoremayberecordedindifferentnotations:decimalacuityandlogMAR.Thesetwonotationscanbeeasilyconvertedeachotherintheneweyechart.Themeasurementsofthisnewchartnotonlyshowedasignificantcorrelationandagoodconsistencywiththeinternationalstandardlogarithmicvisualacuitychart(r=0.932,P<0.01),butalsoindicatedahightest-retestreliability(89%ofretestscoreswerewithin0.1logMARunitsoftheinitialtestscore).CONCLUSION:Theresultsofthisstudysupportthevalidityandreliabilityofdistancevisualacuitymeasurementsusingtheneweyechartinchildrenaged3to5yearsoverawiderangeofvisualacuities,andtheneweyechartisgreatforearl

简介：AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra